THE ACETYLATED STATUS: PRESENT-DAY POINT OF VIEW ON THE SUBJECT (references review)
https://doi.org/10.51523/2708-6011.2009-6-4-5
Abstract
The study of acetylated polymorphism does not lose its actuality not only because plenty of remedies and carcinogenic substances metabolize by means of acetylization reactions, but also because much success has been achieved in the understanding of molecular bases of acetylation. Just these genetically due variations of remedy metabolism are one of the causes of individual peculiarities of pharmacotherapeutic effects. A man has two discovered genes, responsible for the activities of N-acetyltransferase enzyme - NAT1 и NAT2. The research has shown, that some alleles of these genes influence individual sensitivity to single illnesses.
References
1. Середенин, С. Б. Лекции по фармакогенетике / С. Б. Середенин. - М.: Медицинское информационное агенство, 2004. - 303 с.
2. Meyer, U. A. Polymorphism of human acetyltransferases / U. A. Meyer // Environmental Health Perspectives. - 1994. - Vol. 102, № 6. - P. 213-216.
3. Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms / W. H. David [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 2000. - Vol. 9, № 1. - P. 29-42.
4. Molecular mechanism of slow acetylation of drugs and carcinogens in humans / M. Blum [et al.] // Proc. Natl. Acad. Sci. - 1991. - Vol. 88. - P. 5237-5241.
5. Correlation between acetylation phenotype and genotype in Chinese women / B. Zhao [et al.] // Eur. J. Clin. Pharmacol. - 2000. - Vol. 56. - P. 689-692.
6. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population / M. Gross [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 1999. - Vol. 8. - P. 683-692.
7. Ellard, G. A. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis / G. A. Ellard // Clin. Pharmacol. Ther. - 1976. - Vol. 19. - P. 610-625.
8. Hildebrand, M. Determination of acetylator phenotype in Caucasians with caffeine / M. Hildebrand, W. Seifert // Eur. J. Clin. Pharmacol. - 1989. - Vol. 37. - P. 525-526.
9. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk / C. Bouchardy [et al.] // Pharmacogenetics. - 1998. - Vol. 8. - P. 291-298.
10. N-acetyltransferase polymorhisms and colorectal cancer: A HuGe review / N. Brockton [et al.] // Am. J. Epidemiol. - 2000. - Vol. 151. - P. 846-861.
11. Snider, D. E. Jr. Pyridoxine supplementation during isoniazid therapy / D. E. Jr. Snider // Tubercle. - 1980. - Vol. 61. - P. 191-196.
12. Azad Khan, A. K. The disposition and metabolism of sulfasalazine (salicylazosulphapyridine) in man / A. K. Azad Khan, S. C. Truelove, R. Aranson // Br. J. Clin. Pharmacol. - 1982. - Vol. 13. - P. 523-528.
13. Das, K. M. Clinical pharmacokinetics of sulphasalazine / K. M. Das, R. Dubin // Clin. Pharmacikinet. - 1976. - Vol. 1, № 6. - P. 406-425.
14. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis / G. D. Kitas [et al.] // Scand. J. Rheumatol. - 1992. - Vol. 21. - P. 220-225.
15. Spielberg, S. P. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism / S. P. Spielberg // J. Pharmacokinet. Biopharm. - 1996. - Vol. 24. - P. 509-519.
16. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms / D. W. Hein [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 2000. - Vol. 9. - P. 29-42.
17. Johns, L.E. N-acetyl transferase-2 and bladder cancer risk: A meta-analysis / L. E. Johns, R. S. Houlston // Environ. Mol. Mutagen. - 2000. - Vol. 36. - P. 221-227.
18. N-acetyltransferase 2 and bladder cancer: An overview and consideration of the evidence for gene-environment interaction / J. Green [et al.] // Br. J. Cancer. - 2000. - Vol. 83. - P. 412-417.
19. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England / M. R. Welfare [et al.] // Carcinogenesis. - 1997. - Vol. 18. - P. 1351-1354.
20. N-acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women / A. C. Deitz [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 2000. - Vol. 9. - P. 905-910.
21. NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore / A. Seow [et al.] // Carcinogenesis. - 1999. - Vol. 20. - P. 1877-1881.
22. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation / T. Oyama [et al.] // Anticancer Res. - 1997. - Vol. 17. - P. 577-581.
23. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people / T. Katoh [et al.] // Carcinogenesis. - 1998. - Vol. 19. - P. 1803-1807.
Review
For citations:
Satyrova T.V. THE ACETYLATED STATUS: PRESENT-DAY POINT OF VIEW ON THE SUBJECT (references review). Health and Ecology Issues. 2009;(4):31-36. (In Russ.) https://doi.org/10.51523/2708-6011.2009-6-4-5
Views: 265
Email this article 